CELLINK and IISc inaugurate first Center of Excellence for 3D bioprinting in India

9th December 2022

Following an agreement in August of this year, CELLINK and IISc have opened the doors to the country’s first 3D bioprinting Center of Excellence, which will focus on providing researchers tools to advance discoveries in tissue engineering, regenerative medicine and drug discovery

On 9 December 2022, CELLINK, the global leader in developing 3D bioprinters and¬†the Indian Institute of Science (IISc)¬†opened the doors to the first 3D bioprinting¬†Center¬†of¬†Excellence¬†in the Indian subcontinent.¬†Housed¬†in the Centre for¬†BioSystems¬†Science and Engineering (BSSE) at IISc‚Äôs Bengaluru campus,¬†the¬†CoE¬†will provide access to 3D bioprinting systems, enabling researchers to accelerate their work across critical applications with the¬†ultimate goal¬†of improving health outcomes.¬†The¬†CoE¬†was¬†inagurated¬†by¬†Dr¬†Ashwath¬†Narayan¬†CN,¬†Minister of Electronics, Information Technology¬†–¬†Biotechnology, Science and Technology, Higher Education, Skill Development, Entrepreneurship and Livelihood in the Government of Karnataka;¬†Prof¬†Govindan¬†Rangarajan, the¬†Director of¬†IISc;¬†and¬†Ms¬†Tomoko Bylund,¬†CELLINK‚Äôs Head of Sales – APAC.¬†The event was also attended by¬†Dr¬†Vishal US Rao, Group Director and Dean, HCG Cancer Centre, Bengaluru.¬†

The CoE currently houses several CELLINK instruments, including the BIO X, BIO X6 and the BIONOVA X. It will now officially be accessible to the region’s current and future researchers. 

‚ÄúThis center¬†of excellence offers the most cutting-edge and industryleading 3D Bioprinting technology that we at CELLINK have developed, systems that will enable significant strides in research and in developing the future of health. We are extremely proud to be able to partner with IISc, an institute¬†at¬†the forefront of scientific research as can be seen by the¬†new¬†Medical School being led by Director Prof¬†Rangarajan,‚Ä̬†said¬†Ms¬†Tomoko¬†Bylund.

“We are extremely pleased to partner with CELLINK to initiate efforts in this frontier technology which can greatly accelerate development of therapies, drug discovery, personalised medicine and many other applications that can have tremendous impact on human health,” said Prof Rangarajan.

Dr Ashwath Narayan congratulated CELLINK and IISc on this futuristic initiative and wished it success.


Avijit Minocha, Head of Marketing, CELLINK
Phone: +1 617 637 5372
Email: akm@cellink.com

IISc Office of Communications | news@iisc.ac.in


CELLINK is creating the future of health as part of BICO, the world’s leading bioconvergence company. When CELLINK released the first universal bioink in 2016, it democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 700 publications and are trusted by more than 1,000 academic, pharmaceutical and industrial labs. At the forefront of the bioprinting industry, CELLINK aims to alleviate organ donor shortage with biofabricated transplantable organs and remains committed to reducing our dependence on animal testing and increasing efficiencies in drug development with more physiologically relevant bioprinted organ models. Visit cellink.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO. 

 About BSSE 

Housed at the Indian Institute of Science (IISc), India’s premier institution of higher learning and research, the Centre for BioSystems Science and Engineering (BSSE) was founded in 2015 with a vision to develop and apply interdisciplinary approaches for understanding and manipulating biological systems. Since its inception, the Centre has been running a successful PhD programme in the broad area of Bioengineering. The programme was expanded to clinician-scientists, in collaboration with leading medical centres in the country. A new MTech programme in Bioengineering has been initiated in 2022.¬†¬†Research at the Centre spans a spectrum of areas at the interface of biology and the physicochemical sciences, with a focus on problems of importance to clinicians and industry.¬†